Home › Juvenile Myelomonocytic Leukemia › District of Columbia
Juvenile Myelomonocytic Leukemia clinical trials in District of Columbia
3 studies for Juvenile Myelomonocytic Leukemia are looking for participants at sites in District of Columbia.
Cities in District of Columbia
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
- Children's National Medical Center, Washington D.C.
RecruitingPhase 1/2
1 Month – 21 Years · All sexes · Updated Sep 4, 2026 · NCT05849662A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
- Children's National Medical Center, Washington D.C.
RecruitingPhase 1
Ages 1 to 18 · All sexes · Updated Aug 25, 2026 · NCT06247787The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's National Medical Center, Washington D.C.
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.